CL2018001056A1 - Vacuna contra el virus herpes simplex - Google Patents
Vacuna contra el virus herpes simplexInfo
- Publication number
- CL2018001056A1 CL2018001056A1 CL2018001056A CL2018001056A CL2018001056A1 CL 2018001056 A1 CL2018001056 A1 CL 2018001056A1 CL 2018001056 A CL2018001056 A CL 2018001056A CL 2018001056 A CL2018001056 A CL 2018001056A CL 2018001056 A1 CL2018001056 A1 CL 2018001056A1
- Authority
- CL
- Chile
- Prior art keywords
- herpes simplex
- simplex virus
- virus vaccine
- vaccines
- arn
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 241000700584 Simplexvirus Species 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920002477 rna polymer Polymers 0.000 abstract 1
- 241001529453 unidentified herpesvirus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA DESCRIPCIÓN SE RELACIONA CON VACUNAS DE ÁCIDO RIBONUCLEICO (ARN) DEL VIRUS DEL HERPES SIMPLE (VHS), ASÍ COMO A MÉTODOS PARA UTILIZAR LAS VACUNAS Y A COMPOSICIONES QUE COMPRENDEN LAS VACUNAS.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562245159P | 2015-10-22 | 2015-10-22 | |
US201562245031P | 2015-10-22 | 2015-10-22 | |
US201562247576P | 2015-10-28 | 2015-10-28 | |
US201562248252P | 2015-10-29 | 2015-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2018001056A1 true CL2018001056A1 (es) | 2018-10-19 |
Family
ID=58558127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018001056A CL2018001056A1 (es) | 2015-10-22 | 2018-04-20 | Vacuna contra el virus herpes simplex |
Country Status (19)
Country | Link |
---|---|
US (2) | US20180303929A1 (es) |
EP (1) | EP3365009A4 (es) |
JP (2) | JP2018536023A (es) |
KR (1) | KR20180096593A (es) |
CN (1) | CN108472355A (es) |
AU (2) | AU2016342049B2 (es) |
BR (1) | BR112018008090A2 (es) |
CA (1) | CA3002822A1 (es) |
CL (1) | CL2018001056A1 (es) |
CO (1) | CO2018005258A2 (es) |
EA (1) | EA201890999A1 (es) |
IL (1) | IL258833A (es) |
MA (1) | MA46024A (es) |
MX (1) | MX2018004918A (es) |
PE (1) | PE20181531A1 (es) |
PH (1) | PH12018500855A1 (es) |
SG (1) | SG11201803365RA (es) |
TN (1) | TN2018000155A1 (es) |
WO (1) | WO2017070623A1 (es) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
BR112016024644A2 (pt) | 2014-04-23 | 2017-10-10 | Modernatx Inc | vacinas de ácido nucleico |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
ES2937963T3 (es) | 2015-07-21 | 2023-04-03 | Modernatx Inc | Vacunas de enfermedad infecciosa |
US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
MA45209A (fr) | 2015-10-22 | 2019-04-17 | Modernatx Inc | Vaccins contre les maladies sexuellement transmissibles |
TW201729838A (zh) | 2015-10-22 | 2017-09-01 | 現代公司 | 用於水痘帶狀疱疹病毒 (vzv)之核酸疫苗 |
JP6921833B2 (ja) | 2015-10-22 | 2021-08-18 | モデルナティーエックス, インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
MA47016A (fr) | 2015-10-22 | 2018-08-29 | Modernatx Inc | Vaccins contre les virus respiratoires |
EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
JP7080172B2 (ja) | 2015-12-10 | 2022-06-03 | モデルナティエックス インコーポレイテッド | 治療薬の送達のための組成物及び方法 |
US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
IL263079B2 (en) | 2016-05-18 | 2024-05-01 | Modernatx Inc | Relaxin-encoding polynucleotides |
CN109937253B (zh) | 2016-09-14 | 2023-06-30 | 摩登纳特斯有限公司 | 高纯度rna组合物及其制备方法 |
CA3041307A1 (en) | 2016-10-21 | 2018-04-26 | Giuseppe Ciaramella | Human cytomegalovirus vaccine |
US10925958B2 (en) | 2016-11-11 | 2021-02-23 | Modernatx, Inc. | Influenza vaccine |
EP3551193A4 (en) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES |
US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
EP3582790A4 (en) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | VERY POWERFUL IMMUNOGENIC COMPOSITIONS |
US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | RESPIRATORY SYNCYTIAL VIRUS VACCINE |
US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
MA47790A (fr) | 2017-03-17 | 2021-05-05 | Modernatx Inc | Vaccins à base d'arn contre des maladies zoonotiques |
WO2018187590A1 (en) | 2017-04-05 | 2018-10-11 | Modernatx, Inc. | Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
US11160860B2 (en) * | 2017-04-26 | 2021-11-02 | Merck Sharp & Dohme Corp. | HSV antigenic peptides and HSV protein vaccines |
MA49463A (fr) * | 2017-04-26 | 2021-05-05 | Modernatx Inc | Vaccin contre le virus de l'herpès simplex |
MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
JP7386535B2 (ja) * | 2017-08-17 | 2023-11-27 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 単純ヘルペスウイルス糖タンパク質をコードする修飾mRNAワクチン及びその使用 |
WO2019036683A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | ANALYTICAL METHODS BY HPLC |
EP3668971B8 (en) | 2017-08-18 | 2024-05-29 | ModernaTX, Inc. | Rna polymerase variants |
MA49922A (fr) | 2017-08-18 | 2021-06-02 | Modernatx Inc | Procédés pour analyse par clhp |
WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
EP3681514A4 (en) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | RNA VACZINE AGAINST ZIKA VIRUS |
EP3746090A4 (en) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | RSV RNA Vaccines |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
CN109701008B (zh) * | 2019-02-18 | 2022-06-21 | 山东兴瑞生物科技有限公司 | 针对单纯疱疹病毒的治疗性dc复合疫苗及其制备方法 |
US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
CN113795579A (zh) | 2019-02-20 | 2021-12-14 | 摩登纳特斯有限公司 | 用于共转录加帽的rna聚合酶变体 |
EP3999093A4 (en) * | 2019-07-19 | 2023-11-22 | Merck Sharp & Dohme LLC | ANTIGEN GLYCOPROTEIN E POLYPEPTIDES, COMPOSITIONS AND METHODS OF USE THEREOF |
JP2022542032A (ja) * | 2019-07-21 | 2022-09-29 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 治療用ウイルスワクチン |
WO2021197589A1 (en) * | 2020-03-31 | 2021-10-07 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination |
EP3901261A1 (en) | 2020-04-22 | 2021-10-27 | BioNTech RNA Pharmaceuticals GmbH | Coronavirus vaccine |
CN115803333A (zh) | 2020-07-02 | 2023-03-14 | 生命技术公司 | 三核苷酸帽类似物、其制备和用途 |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
EP4304641A1 (en) * | 2021-03-11 | 2024-01-17 | Redbiotec AG | Vaccine compositions and methods for treating hsv |
AU2022336209A1 (en) | 2021-09-03 | 2024-01-18 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
WO2023107999A2 (en) | 2021-12-08 | 2023-06-15 | Modernatx, Inc. | Herpes simplex virus mrna vaccines |
WO2023147090A1 (en) * | 2022-01-27 | 2023-08-03 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
WO1993001301A1 (en) * | 1991-07-05 | 1993-01-21 | The Penn State Research Foundation | Mutant antiviral regulatory proteins |
GB9406498D0 (en) * | 1994-03-31 | 1994-05-25 | Smithkline Beecham Biolog | Novel compounds |
US7094767B2 (en) * | 1994-07-22 | 2006-08-22 | Merck & Co., Inc. | Polynucleotide herpes virus vaccine |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
CA2270282A1 (en) * | 1996-11-04 | 1998-05-14 | Smithkline Beecham Corporation | Novel coding sequences from herpes simplex virus type-2 |
WO2001023414A2 (en) * | 1999-09-30 | 2001-04-05 | University Of Washington | Immunologically significant herpes simplex virus antigens |
CA2411542A1 (en) * | 2000-06-09 | 2001-12-13 | Teni Boulikas | Encapsulation of polynucleotides and drugs into targeted liposomes |
US6998115B2 (en) | 2000-10-10 | 2006-02-14 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
US7708915B2 (en) | 2004-05-06 | 2010-05-04 | Castor Trevor P | Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein |
EP1604688B1 (de) | 2001-06-05 | 2010-02-03 | CureVac GmbH | Stabilisierte Tumorantigen-mRNA mit erhöhtem G/C-Gehalt |
AU2002319668A1 (en) | 2001-07-27 | 2003-02-17 | President And Fellows Of Harvard College | Laminar mixing apparatus and methods |
WO2003028657A2 (en) | 2001-10-03 | 2003-04-10 | The Johns Hopkins University | Compositions for oral gene therapy and methods of using same |
WO2003092665A2 (en) | 2002-05-02 | 2003-11-13 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
EP1691780A2 (en) * | 2003-11-21 | 2006-08-23 | Alza Corporation | Gene delivery mediated by liposome-dna complex with cleavable peg surface modification |
EP1713514B1 (en) | 2004-01-28 | 2021-11-24 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
US8241670B2 (en) | 2004-04-15 | 2012-08-14 | Chiasma Inc. | Compositions capable of facilitating penetration across a biological barrier |
WO2006063249A2 (en) | 2004-12-10 | 2006-06-15 | Justin Hanes | Functionalized poly (ether-anhydride) block copolymers |
US7638558B2 (en) | 2005-04-01 | 2009-12-29 | Intezyne Technologies, Inc. | Polymeric micelles for drug delivery |
US8273339B2 (en) | 2005-04-12 | 2012-09-25 | Nektar Therapeutics | Polymer-based compositions and conjugates of antimicrobial agents |
EP1896082B1 (en) | 2005-06-16 | 2012-12-26 | Nektar Therapeutics | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
WO2007070705A2 (en) * | 2005-12-15 | 2007-06-21 | The Trustees Of The University Of Pennsylvania | Cationic lipid-mediated vectors |
KR101513732B1 (ko) | 2006-02-21 | 2015-04-21 | 넥타르 테라퓨틱스 | 분할된 분해가능한 폴리머 및 이로부터 제조된 컨주게이트 |
CA2652280C (en) | 2006-05-15 | 2014-01-28 | Massachusetts Institute Of Technology | Polymers for functional particles |
CN101489589A (zh) * | 2006-05-19 | 2009-07-22 | 沃尔特及伊莱萨霍尔医学研究院 | 免疫原性组合物 |
JP5872755B2 (ja) * | 2006-07-20 | 2016-03-01 | バイカル インコーポレイテッド | 抗hsv−2ワクチン接種のための組成物および方法 |
EP2061433B1 (en) | 2006-09-08 | 2011-02-16 | Johns Hopkins University | Compositions for enhancing transport through mucus |
EP2120859B1 (en) | 2006-12-21 | 2013-11-20 | Stryker Corporation | Sustained-release formulations comprising bmp-7 crystals |
US8877206B2 (en) * | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
HUE035101T2 (hu) | 2007-09-28 | 2018-05-02 | Pfizer | Ráksejtek célzása nanorészecskék alkalmazásával |
PT2774608T (pt) | 2008-06-16 | 2020-01-17 | Pfizer | Nanopartículas poliméricas carregadas com fármaco e métodos de produção e utilização das mesmas |
WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
SI2285350T1 (en) | 2008-06-16 | 2018-03-30 | Pfizer Inc. | Methods for the preparation of diblock copolymers functionalized with targeting agent for use in the manufacture of therapeutic nanoparticles |
EA020753B1 (ru) | 2008-06-16 | 2015-01-30 | Бинд Терапьютикс, Инк. | Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение |
US20100087337A1 (en) | 2008-09-10 | 2010-04-08 | Bind Biosciences, Inc. | High Throughput Fabrication of Nanoparticles |
JP2012512175A (ja) | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | 治療薬を徐放するための長時間循環性ナノ粒子 |
JP5622254B2 (ja) | 2009-03-31 | 2014-11-12 | 国立大学法人東京大学 | 二本鎖リボ核酸ポリイオンコンプレックス |
WO2010127159A2 (en) | 2009-04-30 | 2010-11-04 | Intezyne Technologies, Incorporated | Polymeric micelles for polynucleotide encapsulation |
CN102712935B (zh) | 2009-11-04 | 2017-04-26 | 不列颠哥伦比亚大学 | 含有核酸的脂质粒子及相关的方法 |
EP2512487A4 (en) | 2009-12-15 | 2013-08-07 | THERAPEUTIC POLYMERNANOPARTICLES WITH CORTICOSTEROIDS AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
US9295649B2 (en) | 2009-12-15 | 2016-03-29 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
EP2512459A4 (en) | 2009-12-15 | 2013-08-07 | THERAPEUTIC POLYMERIC NANOPARTICLES COMPRISING EPOTHILONE AND METHODS OF MAKING AND USING SAME | |
PT2525815E (pt) | 2010-01-24 | 2015-03-05 | Novartis Ag | Micropartículas de polímero biodegradável irradiadas |
US9089537B2 (en) * | 2010-02-26 | 2015-07-28 | The Trustees Of The University Of Pennslyvania | Subunit vaccines for herpes viruses and methods of use |
US8207290B2 (en) | 2010-03-26 | 2012-06-26 | Cerulean Pharma Inc. | Methods and systems for generating nanoparticles |
US20110262491A1 (en) | 2010-04-12 | 2011-10-27 | Selecta Biosciences, Inc. | Emulsions and methods of making nanocarriers |
EP2575895A2 (en) | 2010-05-24 | 2013-04-10 | Merck Sharp & Dohme Corp. | Novel amino alcohol cationic lipids for oligonucleotide delivery |
WO2011163483A2 (en) | 2010-06-25 | 2011-12-29 | Massachusetts Institute Of Technology | Polymers for biomaterials and therapeutics |
SI4005592T1 (sl) * | 2010-07-06 | 2023-03-31 | Glaxosmithkline Biologicals S.A. | Virionom podobni dostavni delci za samopodvojene molekule RNA |
US10307372B2 (en) | 2010-09-10 | 2019-06-04 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
ES2716243T3 (es) * | 2010-10-11 | 2019-06-11 | Glaxosmithkline Biologicals Sa | Plataformas de suministro de antígenos |
US20150056300A1 (en) | 2010-10-22 | 2015-02-26 | Bind Therapeutics, Inc. | Therapeutic nanoparticles with high molecular weight copolymers |
CA3054532C (en) | 2010-11-05 | 2022-07-12 | The Johns Hopkins University | Compositions and methods relating to reduced mucoadhesion |
US20120189700A1 (en) | 2011-01-19 | 2012-07-26 | Zoraida Aguilar | Nanoparticle Based Immunological Stimulation |
JP6099573B2 (ja) * | 2011-01-31 | 2017-03-22 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 新規なヘルペス抗原をコードする核酸分子、それを含むワクチン及びその使用方法 |
US20140066363A1 (en) | 2011-02-07 | 2014-03-06 | Arun K. Bhunia | Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide |
US9795679B2 (en) | 2011-03-31 | 2017-10-24 | Ingell Technologies Holding B.V. | Biodegradable compositions suitable for controlled release |
EP2691079B1 (en) | 2011-03-31 | 2020-06-24 | Ingell Technologies Holding B.V. | Biodegradable compositions suitable for controlled release |
US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
US20140308363A1 (en) | 2011-05-31 | 2014-10-16 | Bind Therapeutics, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
SG10201605537XA (en) * | 2011-07-06 | 2016-09-29 | Novartis Ag | Liposomes having useful n:p ratio for delivery of rna molecules |
ES2670944T3 (es) | 2011-07-21 | 2018-06-04 | Croda International Plc | Copolímeros de bloques de poliéter-poliamida ramificados y métodos de preparación y uso de los mismos |
CA2842039A1 (en) | 2011-08-26 | 2013-03-07 | Arrowhead Research Corporation | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
US8889657B2 (en) | 2011-08-31 | 2014-11-18 | Mallinckrodt Llc | Nanoparticle PEG modification with H-phosphonates |
EP2747761A1 (en) | 2011-09-22 | 2014-07-02 | Bind Therapeutics, Inc. | Methods of treating cancers with therapeutic nanoparticles |
WO2013072929A2 (en) | 2011-09-23 | 2013-05-23 | Indian Institute Of Technology | Nanop article based cosmetic composition |
EP2768530A1 (en) * | 2011-10-11 | 2014-08-27 | Novartis AG | Recombinant self-replicating polycistronic rna molecules |
KR102011048B1 (ko) | 2011-10-18 | 2019-08-14 | 다이서나 파마수이티컬, 인크. | 아민 양이온성 지질 및 그것의 용도 |
KR102272498B1 (ko) | 2011-10-27 | 2021-07-06 | 메사추세츠 인스티튜트 오브 테크놀로지 | 약물 캡슐화 마이크로스피어를 형성할 수 있는, n-말단 상에 관능화된 아미노산 유도체 |
WO2013078199A2 (en) | 2011-11-23 | 2013-05-30 | Children's Medical Center Corporation | Methods for enhanced in vivo delivery of synthetic, modified rnas |
KR20140102759A (ko) * | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
CN104936620B (zh) | 2012-01-19 | 2019-08-09 | 约翰霍普金斯大学 | 增强粘膜渗透的纳米粒子调配物 |
WO2013113326A1 (en) * | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
EP3312155B1 (en) | 2012-02-03 | 2020-08-05 | Rutgers, The State University of New Jersey | Polymeric biomaterials derived from phenolic monomers and their medical uses |
JP2015513788A (ja) | 2012-02-10 | 2015-05-14 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーE.I.Du Pont De Nemours And Company | 高度xジブロックコポリマーの製造、精製及び使用 |
WO2013143555A1 (en) * | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
EA201492055A1 (ru) * | 2012-06-08 | 2015-11-30 | Шир Хьюман Дженетик Терапис, Инк. | ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ |
US20150307542A1 (en) * | 2012-10-03 | 2015-10-29 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
WO2014089486A1 (en) * | 2012-12-07 | 2014-06-12 | Shire Human Genetic Therapies, Inc. | Lipidic nanoparticles for mrna delivering |
AU2014239184B2 (en) * | 2013-03-14 | 2018-11-08 | Translate Bio, Inc. | Methods and compositions for delivering mRNA coded antibodies |
WO2014152030A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Removal of dna fragments in mrna production process |
US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
WO2014152027A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Manufacturing methods for production of rna transcripts |
EP3757570B1 (en) * | 2013-03-15 | 2023-10-11 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
WO2014144767A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
US20160032273A1 (en) | 2013-03-15 | 2016-02-04 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
US20160017313A1 (en) | 2013-03-15 | 2016-01-21 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
TW201534578A (zh) * | 2013-07-08 | 2015-09-16 | Daiichi Sankyo Co Ltd | 新穎脂質 |
BR112016024644A2 (pt) * | 2014-04-23 | 2017-10-10 | Modernatx Inc | vacinas de ácido nucleico |
US20200172928A1 (en) * | 2017-06-05 | 2020-06-04 | The Brigham And Women's Hospital, Inc. | Vero cell lines stably expressing hsv icp0 protein |
-
2016
- 2016-10-21 BR BR112018008090A patent/BR112018008090A2/pt not_active Application Discontinuation
- 2016-10-21 TN TNP/2018/000155A patent/TN2018000155A1/en unknown
- 2016-10-21 EP EP16858403.5A patent/EP3365009A4/en active Pending
- 2016-10-21 US US15/767,618 patent/US20180303929A1/en not_active Abandoned
- 2016-10-21 MX MX2018004918A patent/MX2018004918A/es unknown
- 2016-10-21 WO PCT/US2016/058322 patent/WO2017070623A1/en active Application Filing
- 2016-10-21 PE PE2018000600A patent/PE20181531A1/es unknown
- 2016-10-21 SG SG11201803365RA patent/SG11201803365RA/en unknown
- 2016-10-21 AU AU2016342049A patent/AU2016342049B2/en active Active
- 2016-10-21 JP JP2018541090A patent/JP2018536023A/ja active Pending
- 2016-10-21 CN CN201680075061.1A patent/CN108472355A/zh active Pending
- 2016-10-21 EA EA201890999A patent/EA201890999A1/ru unknown
- 2016-10-21 CA CA3002822A patent/CA3002822A1/en active Pending
- 2016-10-21 MA MA046024A patent/MA46024A/fr unknown
- 2016-10-21 KR KR1020187014340A patent/KR20180096593A/ko unknown
-
2018
- 2018-04-20 PH PH12018500855A patent/PH12018500855A1/en unknown
- 2018-04-20 CL CL2018001056A patent/CL2018001056A1/es unknown
- 2018-04-22 IL IL258833A patent/IL258833A/en unknown
- 2018-05-21 CO CONC2018/0005258A patent/CO2018005258A2/es unknown
-
2021
- 2021-12-16 JP JP2021204272A patent/JP2022037134A/ja active Pending
-
2023
- 2023-08-17 AU AU2023216825A patent/AU2023216825A1/en active Pending
- 2023-10-04 US US18/481,204 patent/US20240173400A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL258833A (en) | 2018-06-28 |
AU2016342049B2 (en) | 2023-05-18 |
JP2018536023A (ja) | 2018-12-06 |
TN2018000155A1 (en) | 2019-10-04 |
CA3002822A1 (en) | 2017-04-27 |
WO2017070623A1 (en) | 2017-04-27 |
AU2023216825A1 (en) | 2023-09-07 |
MA46024A (fr) | 2019-07-03 |
AU2016342049A1 (en) | 2018-06-07 |
BR112018008090A2 (pt) | 2018-11-13 |
MX2018004918A (es) | 2019-04-01 |
CN108472355A (zh) | 2018-08-31 |
EP3365009A4 (en) | 2019-07-03 |
EP3365009A1 (en) | 2018-08-29 |
PE20181531A1 (es) | 2018-09-26 |
JP2022037134A (ja) | 2022-03-08 |
US20240173400A1 (en) | 2024-05-30 |
PH12018500855A1 (en) | 2018-10-29 |
CO2018005258A2 (es) | 2018-11-22 |
EA201890999A1 (ru) | 2018-12-28 |
KR20180096593A (ko) | 2018-08-29 |
US20180303929A1 (en) | 2018-10-25 |
SG11201803365RA (en) | 2018-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018001056A1 (es) | Vacuna contra el virus herpes simplex | |
CL2018001053A1 (es) | Vacuna contra el virus sincicial respiratorio | |
MX2022006603A (es) | Vacuna contra el virus de la influenza de amplio espectro. | |
MD3718565T2 (ro) | Vaccinuri împotriva virusului respirator | |
CO2017011535A2 (es) | Composiciones de ácido obeticólico y métodos de uso | |
UY36766A (es) | Derivados de sulfamoilarilamida ciclados como inhibidores del vhb, procesos de preparación y composiciones farmacéuticas que los contienen | |
BR112016024644A2 (pt) | vacinas de ácido nucleico | |
CL2016003277A1 (es) | Métodos para preparar análogos de nucleótido sustituidos | |
CO2019009215A2 (es) | Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c | |
CO2017002253A2 (es) | Compuesto dirigido a il-23a y tnf-alfa | |
MX2021010060A (es) | Produccion de virus en huevos aviares. | |
DOP2022000085A (es) | Composiciones y métodos para inhibir la expresión del gen alas1 | |
BR112016018654A2 (pt) | Composições de silicato estabilizadas e seu uso como composições antiperspirantes | |
BR112017003462A2 (pt) | coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino. | |
CO2018010359A2 (es) | Constructos de alfavirus vivo atenuado y métodos y usos de los mismos | |
UY36217A (es) | Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso. | |
PE20160596A1 (es) | Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana | |
EA201991319A1 (ru) | Вакцины аттенуированного свиного гриппа и способы их изготовления и применения | |
TR201819130T4 (tr) | Sulu Formülasyonlar, Bunların Üretimi Ve Kullanımı | |
AR106464A1 (es) | Vacuna de virus sincitial respiratorio | |
BR112017027132A2 (pt) | reguladores do nrf2 | |
BR112017027137A2 (pt) | reguladores de nrf2 |